DermWorld Weekly

March 22, 2023:

• Comparing efficacy of JAK inhibitors used in alopecia areata

• DermWorld Insights and Inquiries: Resorcinol’s resourcefulness in hidradenitis suppurativa

• Derm Coding Consult: CMS Targeted Probe and Educate (TPE) reviews are now in full swing

• Lebrikizumab for atopic dermatitis: Two phase 3 trials

• What the end of the COVID-19 PHE means for dermatologists

March 15, 2023:

• Topical cetirizine with minoxidil vs. minoxidil in androgenetic alopecia

• DermWorld Insights and Inquiries: A checkup on immune checkpoint inhibitor-induced subacute cutaneous lupus

• DermWorld Young Physician Focus: Putting the proper safeguards into place

• Safety of UV filters in the U.S. and EU

• Evaluating parental leave policies at medical schools

• FDA reports SCC in capsule around breast implants

March 8, 2023:

• Efficacy of various concentrations of retinol in middle-aged women

• DermWorld Insights and Inquiries: For the win! Championing the use of the term ‘reactive granulomatous dermatitis’ in clinical practice

• Member comment period for new AD guidelines is open

• Should deep shave removal be considered for suspected BCC?

• Former AADA President David Pariser, MD, FAAD, attends President Biden speech, urges president to oppose Medicare cuts

March 1, 2023:

• Isotretinoin: Risk of IBS, ulcerative colitis, and Crohn’s disease?

• DermWorld Insights and Inquiries: Seeing red with dupilumab

• IL-17 inhibitors in psoriasis patients in the real world

• What’s new in the management of cutaneous HPV infection?

• MIPS data submission open, exception deadline approaching

• Keep dermatology’s voice strong: Join the AMA

Feb. 22, 2023:

• How effective are field treatments for actinic keratosis?

• DermWorld Insights and Inquiries: Saving face — The importance of recognizing facial discoid dermatosis

• A systematic review of intralesional treatments for plantar warts

• Risk of needle contamination, complications with hyaluronic acid fillers

• What factors are associated with matching to a dermatology residency?

Feb. 15, 2023:

• AADA addresses lidocaine shortage with manufacturers

• DermWorld Insights and Inquiries: A nail-biting commentary

• Risk of rebound psoriasis flare from systemic corticosteroids

• DermWorld Young Physician Focus: Weighing our options for pediatric care

• Advocacy win: UnitedHealthcare updates prior authorization policy

Feb. 8, 2023:

• A review of newer agents for alopecia areata

• DermWorld Insights and Inquiries: A surgeon’s primary intention is to reduce secondary infection

• CDC investigating possibility of treatment-resistant dermatophytosis

• High-dose clobetasol propionate in patients with cutaneous lichen planus

• Allergens in pediatric sunscreens

Feb. 1, 2023:

• Are topical AK treatments associated with increased risk of SCC?

• DermWorld Insights and Inquiries: A seasoned approach to treating the ‘salt and pepper’ dyspigmentation of systemic sclerosis

• What role does diet play in rosacea?

• Media highlights dermatologists taking action to integrate skin of color into medical training

• Managing patients with DRESS

Jan. 25, 2023:

• Is topical spironolactone effective for acne?

• DermWorld Insights and Inquiries: The ironclad promise of ferroptosis

• Topical lidocaine-prilocaine vs. ice packs for laser hair removal

• Efficacy of tretinoin creams in treating acanthosis nigricans

• Dermatologists’ knowledge of compounding pharmacy regulations

Jan. 18, 2023:

• Have cutaneous manifestations of COVID-19 changed during Delta, Omicron waves?

• DermWorld Insights and Inquiries: Complications of silicone injections – persistence, stigma, and treatment

• AAD releases updated topical therapy guidelines for atopic dermatitis

• DermWorld Young Physician Focus: Juggling parenting and dermatology

• AMA House of Delegates recap

• COVID-19 Public Health Emergency renewed

Jan. 11, 2023:

• Antihistamines as adjunct therapy for alopecia areata

• DermWorld Insights and Inquiries: Acquisition and loss — A tribute to Jouni Uitto, MD, PhD

• Lidocaine shortage: Ask the expert

• Nail clipping histopathology for routine evaluation of melanonychia

• Academy Advisory Board invites members to submit policy resolutions

Jan. 4, 2023:

• Frontal fibrosing alopecia, sunscreen, and actinic damage

• DermWorld Insights and Inquiries: Sniffing out the meaning of perialar intertrigo

• Topical eye medications causing allergic contact dermatitis

• Achieving an itch-free state using topical ruxolitinib

• Deadline extended for MIPS Extreme and Uncontrollable Circumstances exception application

• Academy Advisory Board invites members to submit policy resolutions

Dec. 21, 2022:

• Isotretinoin and the risk of psychiatric events in acne patients

• DermWorld Insights and Inquiries: Holiday greeting 2022

• Risk of skin cancer in patients with chronic cutaneous inflammatory conditions

• Do e-cigarettes affect cutaneous wound healing?

• Treating hidradenitis suppurativa with upadacitinib

Dec. 14, 2022:

• Are nutritional supplements effective for hair loss?

• DermWorld Insights and Inquiries: A Frank discussion about earlobe creases

• DermWorld Young Physician Focus: Zoonotic dermatoses – When the rare and unusual move next door

• A consensus statement on measuring AD control, itch in clinical practice

• How well do patients understand common medical jargon?

• 2022 MIPS: Exemption application

Dec. 7, 2022:

• Recommendations for follow-up of patients with nonmelanoma skin cancer

• DermWorld Insights and Inquiries: Xylazine (“Tranq”) — The potential for loss of life and limb

• Using apremilast off-label in dermatologic disorders

• How does Instagram portray laser surgery?

• Physician legislators in government in 2022

• MIPS 2022 reminders: Preview period, SAFER Guides measure

Nov. 30, 2022:

• Chemotherapeutics for treating actinic keratosis

• DermWorld Insights and Inquiries: Palmar Pagetoid dyskeratosis — A sheep in wolf’s clothing

• A guide to transitioning to JAK inhibitors for AD patients

• Improving recognition of dermatologic conditions in skin of color

• Physician burnout vs. depression

Nov. 16, 2022:

• Novel treatments for chronic spontaneous urticaria

• DermWorld Insights and Inquiries: Unrestricted fascination with restrictive dermopathy

• DermWorld Young Physician Focus: Academy staff offer refresher on top E/M coding errors

• Selecting the right biologic treatment for psoriasis patients

• Do e-visits for isotretinoin management cause interruptions in care?

Nov. 9, 2022:

• Intralesional vs. intramuscular hepatitis B vaccine for common warts

• DermWorld Insights and Inquiries: Hair straighteners and the risk of uterine cancer — More studies are necessary to get this straight

• Alopecia areata: Two investigational JAK inhibitors report positive results

• Soft tissue dermal filler-associated necrosis

• Contact allergens in natural skin care products

Nov. 2, 2022:

• Factors that influence platelet rich plasma efficacy in androgenic alopecia

• DermWorld Insights and Inquiries: Lipodystrophia semicircularis — A lipoatrophy not to get depressed about

• Underlying conditions associated with development of prurigo nodularis

• Psychological therapies in the management of dermatologic diseases

• Facial dermatoses from face masks

Oct. 26, 2022:

• Diagnosing and treating onychomycosis

• DermWorld Insights and Inquiries: Lending a helping hand to our patients with Dupuytren’s disease

• GoodRx launches provider-facing tool for point-of-care savings

• Distinguishing features of pseudocellulitis in pediatric inpatients

• Deucravacitinib vs. apremilast for plaque psoriasis

Oct. 19, 2022:

• Safety of minoxidil for hair disorders in pediatric patients

• DermWorld Insights and Inquiries: Telangiectasias: When is it TEMPI time?

• DermWorld Young Physician Focus: Revisiting physician mental health

• Monkeypox: Recognizing minimal cutaneous involvement or systemic symptoms

• Is there an association of VTE with AD and treatment with JAK inhibitors?

Oct. 12, 2022:

• Type 2 diabetes and CCCA severity

• DermWorld Insights and Inquiries: Fixing the concept of the neutrophilic fixed drug eruption

• What’s the risk of IBD in patients with chronic inflammatory skin diseases?

• Reduced post-infusion cooling prevents chemotherapy-induced alopecia

• Victory! UHC changes Mohs prior authorization, multiple procedure payment reduction policies

Oct. 5, 2022:

• Is there an association between low-dose methotrexate and melanoma?

• DermWorld Insights and Inquiries: Optimizing the dermatologist-patient encounter

• FDA approves first treatment for prurigo nodularis

• Perioperative practices in dermatologic surgery

• Tacrolimus for treating oral lichen planus

Sept. 28, 2022:

• Treating warts with needle-free fluorouracil injection

• DermWorld Insights and Inquiries: Tag, you’re it!

• Clinical outcomes of chronic urticaria after two years

• Clues to help identify patients with ocular rosacea

• Study compares AI and dermatologist judgments of melanoma thickness

Sept. 21, 2022:

• Does low-dose oral minoxidil affect blood pressure, heart rate?

• DermWorld Insights and Inquiries: The emergence of rituximab-induced pyoderma gangrenosum — An alert to dermatologists

• DermWorld Young Physician Focus: PBM tactics increase drug prices, lower patient access

• Filler reversal with hyaluronidase

• House bill would eliminate Medicare conversion factor cut in 2023

• House passes prior authorization relief bill

Sept. 14, 2022:

• Real-world methotrexate use in pediatric patients with plaque psoriasis

• DermWorld Insights and Inquiries: The ever-changing world of nevus sebaceus

• New anti-wrinkle injection receives FDA approval

• FDA approves first TYK2 inhibitor deucravacitinib

• Managing hair loss after COVID-19 infection

Sept. 7, 2022:

• Are concentrations higher than 5% minoxidil of benefit for androgenic alopecia patients?

• DermWorld Insights and Inquiries: BASCULE syndrome: Is something brewing with Bier spots?

• Emollient creams exhibit diverse effects on skin barriers of AD patients

• Complications with fat and cellulite reduction devices

• AADA responds to Medicare 2023 payment proposals

Aug. 31, 2022:

• Isotretinoin lab monitoring in acne treatment

• DermWorld Insights and Inquiries: Metformin mania — Is it an adequate chemopreventive agent for skin cancer?

• Monkeypox: A dermatologic primer

• AADA, sister societies address drug shortage with FDA

• Characterizing three profiles for bullous pemphigoid

Aug. 24, 2022:

• Comparing efficacy and safety of laser treatments for tattoo removal

• DermWorld Insights and Inquiries: The pressure to prevent pressure ulcers

• Derm Coding Consult: AMA releases new codes for monkeypox virus testing and vaccination

• Ask the expert: Fighting for fair Medicare reimbursement

• AAD mourns the passing of Samuel L. Moschella, MD

Aug. 17, 2022:

• Do dietary exclusions improve atopic dermatitis?

• DermWorld Insights and Inquiries: Promising therapeutic developments for cutaneous lupus erythematosus — Interfering with interferon

• Derm Coding Consult: Dermatology injection code utilization

• DermWorld Young Physician Focus: Pulling back the curtain on pharmacy benefits managers

• At-home treatment of cutaneous warts combining in-person, telederm consultations

Aug. 10, 2022:

• Tetracyclines may pose greater hyperpigmentation risk

• DermWorld Insights and Inquiries: Forty years of marriage, dermatology, inequities, and gratitude

• Registry now accepting monkeypox cases

• AAD statement on National Academies of Sciences, Engineering, and Medicine's report on environmental impact of sunscreens and potential impacts of changes in sunscreen usage

• New federal guidance on nondiscrimination in telehealth services

• FDA issues warning to companies selling unapproved new drugs for mole and skin tag removal

Aug. 3, 2022:

• Dutasteride microinjections with oral minoxidil vs. oral minoxidil for androgenetic alopecia

• DermWorld Insights and Inquiries: Infantile digital fibromatosis – Inclusions and exclusions

• CMS outlines payment changes for 2023 in proposed fee schedule

• FDA approves roflumilast for treatment of plaque psoriasis for patients 12 and older

• Treating patients with skin-picking disorder

July 27, 2022:

• Facial hyperhidrosis: Botulinum toxin A injection vs. topical glycopyrrolate

• DermWorld Insights and Inquiries: JAKne is on the horizon

• Dupilumab for chronic prurigo, chronic idiopathic pruritus

• Safety of Q-switched alexandrite laser in darker skin

• Chlormethine for mycosis fungoides

July 20, 2022:

• FDA approves first vitiligo treatment for skin repigmentation

• DermWorld Insights and Inquiries: A single case report has the potential to change the world — Could JAK inhibition alter the trajectory of multicentric reticulohistiocytosis?

• OIG initiates audit of dermatologist claims using modifier 25

• DermWorld Young Physician Focus: Counseling patients on cosmetic concerns

• June AMA House of Delegates has implications for dermatology

July 13, 2022:

• Androgenic skin conditions and hormonal IUDs

• DermWorld Insights and Inquiries: COVID-19 can nail you in so many ways

• What does Europe’s tattoo ingredient ban mean for North America?

• Lab testing for pediatric patients using isotretinoin

July 6, 2022:

• Long-term recurrence rates of actinic keratoses

• DermWorld Insights and Inquiries: Isotretinoin and diabetes — Of familiarity and surprise

• What physicians should know about monkeypox

• Anti-PD-1 therapy for melanoma patients after achieving a complete response

• Asymptomatic dermatologic surgery patients who test positive for COVID-19

June 29, 2022:

• Psoriasis treatment adherence: Adalimumab vs. ixekizumab

• DermWorld Insights and Inquiries: When to see red in linear erythronychia — Malignant onychopapilloma

• Dermatologist Jack Resneck Jr., MD, FAAD, becomes new AMA president

• Rare cutaneous malignancies in skin of color

• Dermatology residency: Allopathic vs. osteopathic vs. international

June 22, 2022:

• Molluscum contagiosum: 35% trichloroacetic acid vs. autoinoculation

• DermWorld Insights and Inquiries: Is it a waste for dermatologists to order fecal calprotectin?

• Physician experience with virtual scribes

• Derm Coding Consult: Cigna to delay modifier 25 policy

• Ustekinumab for pediatric plaque psoriasis

June 15, 2022:

• FDA approves first systemic treatment for alopecia areata

• DermWorld Insights and Inquiries: Aluminum can cause allergic contact dermatitis — Allergen of the Year 2022

• DermWorld Young Physician Focus: Academy leadership programs position young physicians for success

• FDA approves dupilumab for children 6 months to 5 years of age with AD

• Risk of vitamin D deficiency in Black patients with CCCA

June 8, 2022:

• The administrative burden of prescribing isotretinoin

• DermWorld Insights and Inquiries: Sweating over acquired idiopathic generalized anhidrosis

• AADA counters IPMG objections to iPLEDGE improvements

• Actinic keratosis guidelines updated to reflect tirbanibulin research

• FDA updates recommendations for the use of Renuvion/J-Plasma device

• Topical treatment improves hyperpigmentation in skin of color

June 1, 2022:

• What’s new in adult acne over the last two years?

• DermWorld Insights and Inquiries: Granulomatous cheilitis — Back to the Future

• Derm Coding Consult: Cigna’s new modifier 25 policy

• Adverse events associated with injectable fillers

• FDA approves tapinarof for psoriasis

• MIPS automatic EUC applies to designated areas in New Mexico

May 25, 2022:

• Placebo regrowth rate in alopecia areata trials

• DermWorld Insights and Inquiries: The globalization of monkeypox

• AADA renews calls for iPLEDGE improvements with IPMG, FDA

• Seeking comments on atopic dermatitis guidelines on topical therapies

• Ruxolitinib cream for cutaneous lichen planus

May 18, 2022:

• Abrocitinib efficacy after switching from dupilumab

• DermWorld Insights and Inquiries: Coming to grips with lymphocytic thrombophilic arteritis

• DermWorld Young Physician Focus: Protecting dermatologic scope of practice

• Seeking comments on atopic dermatitis guidelines on topical therapies

• New gel effective for excessive underarm sweating

May 11, 2022:

• Sexual dysfunction associated with finasteride use in men with androgenetic alopecia

• DermWorld Insights and Inquiries: Lagging ahead — LAG-3 checkpoint inhibition for advanced melanoma

• FDA grants fast track designation for ichthyosis therapy

• An analysis of popular HS content on TikTok

• Academy Advisory Board invites members to submit policy resolutions

• 2022 MIPS EUC, Promoting Interoperability hardship exception applications available

May 4, 2022:

• Plantar warts: Local hyperthermia vs. cryotherapy

• DermWorld Insights and Inquiries: Eruptive pseudoangiomatosis is real

• Intralesional methotrexate vs. triamcinolone acetonide for nail matrix psoriasis

• Report shows physician pay is on the rise

• STD surge continues

April 27, 2022:

• A novel treatment for molluscum contagiosum?

• DermWorld Insights and Inquiries: Eye-opening news about oxymetazoline

• Trends in prescribing spironolactone for acne, HS in adolescents

• Racial biases in medical notes may contribute to health disparities

• FDA issues warning about skin lightening products

April 20, 2022:

• Which biologics are most effective for psoriasis?

• DermWorld Insights and Inquiries: One Toker over the line — Clarifying Toker cell hyperplasia in Zuska disease and its relationship to hidradenitis suppurativa

• DermWorld Young Physician Focus: Re-examining itch

• Are specific body sites prone to surgical site infections?

• COVID-19 public health emergency renewed

• The non-physician dermatology workforce

April 13, 2022:

• Is there an association between isotretinoin and adverse neuropsychiatric outcomes?

• DermWorld Insights and Inquiries: Early recognition of rituximab-induced late onset neutropenia is essential

• Election winners Dialogues interview

• Treating seborrheic keratosis with hydrogen peroxide

• IL-17 blockade reduces psoriatic lesional expression of COVID-19 receptor

April 6, 2022:

• A comprehensive review of rosacea treatments

• DermWorld Insights and Inquiries: “Stepping up” to off-label dosing of biologics

• Improving itch in prurigo nodularis patients

• What acne treatments are being recommended on YouTube?

• A review of systemic treatments for vitiligo

March 30, 2022:

• The rankings are in: Minoxidil, finasteride, and dutasteride for male androgenetic alopecia

• DermWorld Insights and Inquiries: Bowel-associated dermatosis-arthritis syndrome (BADAS) — The story behind the acronym

• Acne and insulin resistance

• Health Care Provider Protection Act becomes law

• What dermatologists should know about VEXAS syndrome

March 23, 2022:

• Acitretin: A new therapy for onychomycosis?

• DermWorld Insights and Inquiries: A new wrinkle in the diagnosis of cystic fibrosis?

• Injury and litigation in cutaneous laser surgery

• Switching from oral to subcutaneous methotrexate

• FDA warns against use of Renuvion/J-Plasma device for certain aesthetic procedures

• Extension of COVID-19 telehealth waivers

March 16, 2022:

• Comparing four cSCC staging systems

• DermWorld Insights and Inquiries: Mind the gap

• DermWorld Young Physician Focus: Talking points

• Potassium monitoring in women on spironolactone

• Using medical cannabis to treat dermatologic conditions

March 9, 2022:

• Eight misconceptions about photoprotection in skin of color

• DermWorld Insights and Inquiries: IL-36 and generalized pustular psoriasis — L’chaim!

• Derm Coding Consult: Novitas revises shave removal coverage policy to include malignant skin lesions

• Is spironolactone use associated with risk of cancer?

• MIPS extreme and uncontrollable circumstances applications reopened

March 2, 2022:

• Biotin beware: Physician, patient knowledge about lab interference

• DermWorld Insights and Inquiries: The rhythm of RIME

• Infections in children treated with dupilumab

• Cutaneous adverse events are associated with increased survival in patients on anti-PD-1, anti-PD-L1 therapy

• Will biosimilars cut spending for biologic therapy in the U.S.?

Feb. 23, 2022:

• Frontal fibrosing alopecia: The effects of sunscreens and moisturizers

• DermWorld Insights and Inquiries: The vexing verruciform xanthoma

• DermWorld Young Physician Focus: The patient experience — there’s an app for that

• Red light vs. blue light therapies for acne

• Diversity in dermatology clinical trials

Feb. 16, 2022:

• A review of calcipotriol plus 5-fluorouracil for actinic keratosis

• DermWorld Insights and Inquiries: Vascular Ehlers-Danlos syndrome: From rupture to rapture?

• Delayed complications for FDA-approved HA dermal fillers

• What every physician needs to know about the Disabilities Act

• Safety of tacrolimus for children with AD

Feb. 9, 2022:

• Tinted sunscreens: A practical guide to counseling patients

• DermWorld Insights and Inquiries: Lightening the cutaneous and emotional burden of melasma — cysteamine’s role

• Nemolizumab plus topicals improve AD itch

• Is there an association between alopecia areata and retinal diseases?

• Treating Netherton syndrome with dupilumab

Feb. 2, 2022:

• A high-fiber diet may affect immunotherapy response for melanoma patients

• DermWorld Insights and Inquiries: An old dog with a new trick — High dose intralesional steroids in hidradenitis suppurativa

• Derm Coding Consult: CMS announces new Place of Service code for telehealth provided to patients in their homes

• 2022 physician depression, burnout survey

• Topical calcineurin inhibitors for pediatric atopic dermatitis

Jan. 26, 2022:

• Allergens in hand sanitizers

• DermWorld Insights and Inquiries: Eccrine syringofibroadenoma — Sweating over the details

• Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice – Part 8

• New AAD guidelines address comorbidities and atopic dermatitis

• FDA approves abrocitinib, upadacitinib for atopic dermatitis

• AMA House of Delegates recap

Jan. 19, 2022:

• Finasteride: Topical vs. oral for male androgenetic alopecia

• DermWorld Insights and Inquiries: Probing pityriasis rosea in pregnancy

• Derm Coding Consult: Dermatology benign, premalignant, and malignant destruction code utilization

• DermWorld Young Physician Focus: To stress is human

• Supreme Court upholds CMS vaccine mandate, strikes down OSHA

Jan. 12, 2022:

• Probiotics for atopic dermatitis?

• DermWorld Insights and Inquiries: Tarrying for tapinarof

• Derm Coding Consult: Patch testing unit of service reduction averted

• Research gap years may impact successful dermatology match

• Patient satisfaction with live video telehealth declines

Jan. 5, 2022:

• Cicatricial alopecia following ACD from hair dye

• DermWorld Insights and Inquiries: Coming full circle (almost) — Low dose oral minoxidil for alopecia

• FDA approves atopic dermatitis biologic

• Risk factors for positive surgical margins after excision of MCC

• Academy Advisory Board invites members to submit policy resolutions

Dec. 22, 2021:

• Can COVID-19 be transmitted through the skin?

• DermWorld Insights and Inquiries: Holiday greeting 2021

• Derm Coding Consult: Anthem updates virtual visit policies

• No Surprises Act takes effect Jan. 1, 2022

• An emerging preservative allergen?

Dec. 15, 2021:

• Female-pattern hair loss: Effect of bicalutamide on minoxidil-induced hypertrichosis

• DermWorld Insights and Inquiries: Speculating on spicules — Our incomplete knowledge of trichodysplasia spinulosa

• DermWorld Young Physician Focus: I’m not the enemy

• Congress addresses impending Medicare cuts

• Is phototherapy an effective treatment for atopic dermatitis?

Dec. 8, 2021:

• Factors that may predict chronic spontaneous urticaria recurrence

• DermWorld Insights and Inquiries: Propranolol and neutrophilic dermatoses — Can beta-blockade be better blockade?

• Feedback requested: Actinic keratosis clinical guideline update

• 2021 Annual Report of DataDerm™

• iPLEDGE deadline approaching

Dec. 1, 2021:

• Risk of COVID-19 infection in atopic dermatitis patients

• DermWorld Insights and Inquiries: The nexus of VEXAS syndrome

• Skin and gut microbiome in hidradenitis suppurativa

• Is imiquimod cream effective for keratoacanthomas?

• Eye care products that may cause patch test reactions

• CMS, OSHA vaccination deadline approaching

• Reminder: Check your final 2021 MIPS eligibility status

Nov. 17, 2021:

• Intralesional acyclovir for cutaneous warts

• DermWorld Insights and Inquiries: Biotin supplementation for hair and nail health — Does it pass the test?

• DermWorld Young Physician Focus: Making progress

• AADA urges iPLEDGE sponsors to delay new platform implementation

• Pityriasis rubra pilaris-like eruption after mRNA COVID-19 vaccine

• All individual MIPS clinicians to receive automatic extreme and uncontrollable circumstances exemption

Nov. 10, 2021:

• CMS, OSHA release rules expanding workforce vaccination requirements

• DermWorld Insights and Inquiries: Recognizing toxic epidermal necrolysis-like acute cutaneous lupus erythematosus ASAP

• Prognostic value of lymphovascular invasion in early-stage Merkel cell carcinoma

• Sunscreen use and blood concentrations of benzene

• Does exercise influence skin aging, skin health, or androgenetic alopecia?

Nov. 3, 2021:

• Facial contact dermatitis from cosmetic allergens

• DermWorld Insights and Inquiries: Humbled again — Alopecic and aseptic nodules of the scalp

• Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice – Part 7

• Progression of frontal fibrosing alopecia in Black women

• What UnitedHealthcare’s Designated Diagnostic Provider program may mean for you: Protect your referral relationship with your dermatopathologist

Oct. 27, 2021:

• COVID-19 and nails: A review of clinical findings

• DermWorld Insights and Inquiries: Taking woolly hair to heart

• Derm Coding Consult: CMS revises Advance Beneficiary Notice of Non-coverage (ABN) requirements

• Categorization of cutaneous COVID-19 vaccine reactions

• FDA approves first interchangeable biosimilar to adalimumab

• Facing a trifecta of Medicare physician payment cuts Jan. 1, 2022, here’s what the AADA is demanding on behalf of the specialty

Oct. 20, 2021:

• AADA advocacy results in FDA approving iPLEDGE modifications

• DermWorld Insights and Inquiries: Probing pediatric pigmented purpuras

• DermWorld Young Physician Focus: Staying connected

• Scabies treatment may be less effective

• Hidradenitis suppurativa hospital readmission rate

• AAD mourns the passing of Gloria Flippin Graham, MD, who helped establish the Women’s Dermatologic Society

• HHS renews public health emergency

Oct. 13, 2021:

• How does wearing occlusive gloves impact hand eczema?

• DermWorld Insights and Inquiries: What’s up in Down syndrome?

• Relief funds available for health care providers, including some reserved for rural practices. Apply by Oct. 26.

• New AAD-supported ICD-10 codes for moisture-associated skin damage approved

• FDA warns against use of needle-free devices for dermal filler injections

• CMS updates MIPS 2022 payment adjustments, 2020 MIPS performance feedback

• United adjusts dermpath program, delays until 2022

Oct. 6, 2021:

• A review of oral nail growth supplements

• DermWorld Insights and Inquiries: Granular detail on granular parakeratosis

• Coding guidance on reporting lesion services

• Implementation of COVID-19 phototherapy guidelines

• FDA recalls compounding pharmacy products

Sept. 29, 2021:

• Is HPV vaccination associated with clearance of common warts?

• DermWorld Insights and Inquiries: Positively perplexing — Determining the meaning of CD30 positivity

• FDA proposes new guidance on OTC sunscreen products and safety information

• FDA approves first topical JAK inhibitor for atopic dermatitis

• COVID-19 infection in a vaccinated health system

Sept. 22, 2021:

• What treatment is most effective for refractory spontaneous urticaria?

• DermWorld Insights and Inquiries: Following up on “A Trend I Cannot Endorse”

• DermWorld Young Physician Focus: Serendipity

• Lawsuit filed against FDA for alleged inaction on hair loss drug potential side effects

• Dermatologist Seemal R. Desai, MD, FAAD, reappointed to FDA Pharmacy Compounding Advisory Committee

• Hurricane Ida triggers MIPS extreme and uncontrollable circumstances policy

Sept. 15, 2021:

• Worsening psoriasis after COVID-19 vaccination

• DermWorld Insights and Inquiries: Is ivermectin an old drug with new tricks?

• Frontal fibrosing alopecia and facial care products

• Biden administration announces employee vaccination mandates

• Do hormones, reproduction play a role in incident rosacea?

Sept. 8, 2021:

• A review of spironolactone for androgenetic alopecia

• DermWorld Insights and Inquiries: Alarming but benign – The enigma of acute hemorrhagic edema of infancy

• What are the long-term clearance rates for actinic keratosis interventions?

• FDA issues safety warning for JAK inhibitors that treat inflammatory conditions

Sept. 1, 2021:

• Which dermatology patients should receive a third dose of mRNA vaccine?

• DermWorld Insights and Inquiries: Shedding light on the hydroa vacciniforme-like lymphoproliferative disorder

• Obesity, diabetes associated with reduced response to biologics

• No-show rate reduced with teledermatology

• Information blocking: Make your voice heard

Aug. 25, 2021:

• TNF inhibitors vs. IL-17/IL-23 inhibitors for psoriasis and PsA

• DermWorld Insights and Inquiries: Immediate pathology report release to patients — Is the 21st Century CURES Act worse than the disease?

• Itch in skin of color

• Quantifying skin conditions from mask-wearing

• 2020 MIPS performance feedback, final score, and 2022 payment adjustment

Aug. 18, 2021:

• Evaluating diagnostic accuracy across Fitzpatrick phototypes, skin of color

• DermWorld Insights and Inquiries: Striving for hard facts about water softening in atopic dermatitis

• DermWorld Young Physician Focus: Fitting it all in

• Seeking comments on urticaria guideline

• COVID-19 breakthrough infections in vaccinated health care workers

Aug. 11, 2021:

• Topical tofacitinib for alopecia areata affecting facial hair

• DermWorld Insights and Inquiries: Monitoring infantile hemangiomas — What’s the score?

• Is there an effective treatment for skin picking disorder?

• Chilblains before and during the COVID-19 pandemic

• Efficacy of ruxolitinib cream in vitiligo patients

Aug. 4, 2021:

• Probiotic supplements improve atopic dermatitis symptoms

• DermWorld Insights and Inquiries: Keeping abreast of drug-induced cutaneous lupus

• From mentoring LGBT dermatologists, to caring for HIV patients, GALDA looks back on its 40-year journey

• FDA approves treatment for adult dermatomyositis

• Overcoming hurdles in telemedicine

July 28, 2021:

• OTC hair growth therapies for skin of color patients

• DermWorld Insights and Inquiries: Putting a finger on the diagnosis of Achenbach syndrome

• Celiac disease: Which skin conditions may be related?

• Here’s what it takes to launch a successful Skin Cancer Awareness Month

• A review of TYK2 inhibitors for dermatologic conditions

July 21, 2021:

• AADA secures iPLEDGE win

• DermWorld Insights and Inquiries: Getting to the heart of neonatal lupus erythematosus

• DermWorld Young Physician Focus: Advancing the cause

• Cutaneous reactions after mRNA COVID-19 vaccines

• AMA House of Delegates adopts two resolutions: Non-physician titles, information-blocking rules

July 14, 2021:

• Acne scarring treatments: What’s most effective?

• DermWorld Insights and Inquiries: Assessing the significance of a Long-Developed Habit — The role of LDH in dermatology

• Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice – Part 6

• Share your comments on the AD comorbidity guideline

• CMS makes sweeping changes to MIPS quality benchmarks

• JAAD ranks No. 1 among dermatology journals

July 7, 2021:

• OTC eczema products with high prevalence of potentially allergenic ingredients

• DermWorld Insights and Inquiries: Progress in pemphigus — Solidifying rituximab’s role

• Share your comments on the AD comorbidity guideline

• An open notes experiment before the information blocking rule

• Sun-damaged skin and subsequent development of cutaneous squamous cell carcinoma

• Provider Relief Fund reporting deadline extended

June 30, 2021:

• Treating atopic dermatitis with cognitive behavioral therapy: Does it work?

• DermWorld Insights and Inquiries: Deep learning in dermatopathology

• Sublingual tofacitinib for alopecia areata

• Biologic psoriasis treatments and risk of nonmelanoma skin cancers

• AAD adopts updated ACCME disclosure standards for educational presenters

• AADA's Coding Community will close permanently Aug. 2, 2021

June 23, 2021:

• Subcutaneous vs. oral methotrexate for psoriasis patients

• DermWorld Insights and Inquiries: Dermatology and dermatopathology awake — now is the time to embrace the AI revolution

• Young Physician Focus: Looking back and forging ahead

• OSHA mandates COVID-19 safety plans for health care workplaces

• Is male frontal fibrosing alopecia linked to sunscreen, hair care products?

• AAD mourns the passing of Robert J. Friedman, MD, MSc

• Join efforts to increase COVID-19 vaccination rates

June 16, 2021:

• Rituximab vs. mycophenolate mofetil for pemphigus vulgaris

• DermWorld Insights and Inquiries: Like the tumor itself, knowledge about DFSP is expanding wider and deeper

• Derm Coding Consult: Applying the 2021 E/M coding concepts in everyday practice – Part 5

• Methotrexate may decrease effectiveness of Pfizer-BioNTech COVID-19 vaccine

• Academy member chosen as AMA president-elect

• Provider Relief Fund reporting deadline extended

June 9, 2021:

• Merkel cell carcinoma survival by anatomic site

• DermWorld Insights and Inquiries: Insult to injury — COVID-19-associated mucormycosis

• Microneedling with topical therapies for melasma

• Photosensitivity reaction from benzodiazepines

• Does wildfire air pollution increase atopic dermatitis, itch appointments?

• AADA opposes physician assistant name change

June 2, 2021:

• Acne and enthesitis: Is there an association?

• DermWorld Insights and Inquiries: Touching on contact pemphigus and pemphigus-like eruptions due to imiquimod

• Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice – Part 4

• Cutaneous adverse events of immune checkpoint inhibitors

• Pharmaceutical testing detects high levels of benzene in some sunscreen products

• Timolol as a high-value treatment for wounds

• DataDerm™: 2020 MIPS reporting brief

May 26, 2021:

• Managing itch: Wearable sensor quantifies symptoms

• DermWorld Insights and Inquiries: Stevens-Johnson Syndrome-toxic epidermal necrolysis — The aftermath

• Bringing diversity to Academy committees and task forces

• Is abrocitinib effective for moderate-to-severe atopic dermatitis patients?

• AMA survey shows more than 50% of physicians work outside private practice

• CMS reweights MIPS cost category

May 19, 2021:

• Differentiating early squamous cell carcinoma from actinic keratosis

• DermWorld Insights and Inquiries: Epidemic of melanoma or epidemic of scrutiny?

• AAD Board selects Keyvan Nouri, MD, MBA, as next assistant secretary-treasurer

• DermWorld Young Physician Focus: Coming through the other side

• Older Americans turn to online ratings to choose physicians

• Apply for a research grant to support understudied hair disorders

• FDA publishes notice about environmental impact of certain sunscreen ingredient

May 12, 2021:

• Telogen effluvium diagnosis during the COVID-19 pandemic

• DermWorld Insights and Inquiries: For patients with erythropoietic protoporphyria the tide has come in

• Derm Coding Consult: How does your use of benign and malignant excision codes compare to the derm average?

• Clear vs. standard masks during outpatient surgical encounters

• Nationwide global period audit underway

• Comparative effectiveness trials for topical medications

May 5, 2021:

• Is dutasteride an effective treatment for frontal fibrosing alopecia?

• DermWorld Insights and Inquiries: Digging deeper into lupus erythematosus panniculitis

• Which herbal supplements may affect autoimmune skin diseases?

• Risk of allergic reaction to COVID-19 vaccine low among patients with allergic skin diseases

• Grant opportunity: Help increase minority representation in lupus-related clinical trials

• Academy Advisory Board invites members to submit policy resolutions

April 28, 2021:

• Acne: Clindamycin-tretinoin vs. benzoyl peroxide-adapalene

• DermWorld Insights and Inquiries: Do not get burned by missing Staphylococcal scalded skin syndrome

• Is daylight photodynamic therapy effective for actinic keratosis?

• Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice – Part 3

• OIG plans report on dermatologist use of modifier 25

• Comorbidity screening for hidradenitis suppurativa patients

• What does the PHE extension mean for telehealth codes?

April 21, 2021:

• Do hydrolyzed collagen supplements affect skin aging?

• DermWorld Insights and Inquiries: Nailing down the treatment for ungual melanoma in situ

• Young Physician Focus: A little help from my friends

• Isotretinoin management: Store-and-forward vs. live-interactive telemedicine

• Derm Coding Consult: Audits for skin biopsies, repairs on the rise

• Share examples of patient harm caused by early release of electronic health information

April 14, 2021:

• Pulsed dye laser versus ablative fractional CO2 laser for hypertrophic scars

• DermWorld Insights and Inquiries: LIDA rose the insulin requirement

• Actinic keratosis clinical guideline published

• Do mucocutaneous eruptions correlate with COVID-19 severity?

• What do consumers recall from sunscreen labels?

April 7, 2021:

• Applying 2021 E/M coding concepts in everyday practice – Part 2

• DermWorld Insights and Inquiries: Keeping an eye on melanoma

• AAD collaborates with OM1 to enhance DataDerm™

• Phase III results revealed for molluscum contagiosum treatment

• AADA advocates for improved safety oversight for dermal fillers

• Your patients can help the Academy raise awareness about skin cancer

• Payment Protection Program extended

March 31, 2021:

• Studies show skin rashes are highly predictive of positive COVID-19 results

• DermWorld Insights and Inquiries: Netherton syndrome — From apex to nether

• New AAD research grant focuses on understudied hair disorders

• How does COVID-19 impact patients with bullous pemphigoid, pemphigus?

• FDA accepts AADA’s recommendation to improve access to quinacrine

• The AAD Virtual Career Fair is virtually here!

March 24, 2021:

• Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice — Part 1

• DermWorld Insights and Inquiries: Lipschütz ulcers — Not only for women

• Imiquimod vs. photodynamic therapy for actinic keratosis of the scalp

• No more waiting on EHRs for MIPS!

• Is mycophenolate mofetil effective for the treatment of cutaneous lichen planus?

• Does maternal autoimmune disease have an impact on offspring?

March 17, 2021:

• COVID-19 in melanoma patients

• DermWorld Insights and Inquiries: Hoops and happiness — Having the courage to take a shot

• DermWorld Young Physician Focus: Forging ahead

• Chemical peels for melasma in patients with skin of color

• Monitoring patients on methotrexate for lab abnormalities

• Vitiligo patients share struggles, therapeutic needs with FDA

March 10, 2021:

• Periungual warts: Is intralesional antigen immunotherapy effective?

• DermWorld Insights and Inquiries: A shot in the dark

• How does baricitinib fare in alopecia areata?

• Do calcineurin inhibitors, phototherapy have a risk of skin cancer, lymphoma?

• UHC extends application deadline for Designated Diagnostic Provider Program

March 3, 2021:

• The latest on the association between diet and acne

• DermWorld Insights and Inquiries: Time to reassess messing around with steroids and psoriasis

• Is intralesional 5-FU effective for nonmelanoma skin cancer?

• Topical CBD for skin conditions: The known and unknown

• 2021 AAD election: View ballot book, prepare to cast vote

• CMS announces automatic exemption for MIPS 2020 performance period, extended deadline for COVID relief

• When is repayment due for CMS' advance payment program?

Feb. 24, 2021:

• COVID-19 vaccination for patients on immunotherapies: An evidence-based guide

• DermWorld Insights and Inquiries: Multiple pilomatricomas by the numbers

• DermWorld Young Physician Focus: Do you take the ‘wait and see’ approach in your practice?

• FDA approves HA dermal filler for chin retrusion

• United to roll out new Designated Diagnostic Provider program; deadline to apply Feb. 28

• Short-term PPP window open for smaller businesses

• Meet the candidates for the 2021 AAD election

Feb. 17, 2021:

• FDA approves cemiplimab for advanced BCC

• DermWorld Insights and Inquiries: Honing in on diffuse dermal angiomatosis

• New JAK inhibitor shows notable PASI score improvement

• Physician perceptions of people with disabilities

• Minocycline foam label updated with new data

• CDC issues quarantine recommendations for vaccinated health care workers

Feb. 10, 2021:

• FDA clears device to improve cellulite

• DermWorld Insights and Inquiries: Leishmania episode 1a — attack of the clones

• Distance traveled: Dr. Lim’s diversity focus as Academy president still relevant today

• Treating vitiligo with apremilast and narrowband UVB in skin of color

• Isotretinoin vs oral antibiotics: Risk of depression

Feb. 3, 2021:

• How effective are oral hair growth supplements?

• DermWorld Insights and Inquiries: Going green — The complexities of the green nail syndrome

• A practical guide for managing hidradenitis suppurativa patients

• ABD selects new executive director

• How effective are educational brochures at encouraging skin cancer screenings?

• Academy Advisory Board invites members to submit policy resolutions

Jan. 27, 2021:

• Can dermatology employers require employees to receive the COVID-19 vaccine?

• DermWorld Insights and Inquiries: Playing the field — Introducing tirbanibulin for actinic keratosis therapy

• DermWorld Young Physician Focus: Settling into the New Year

• FDA grants orphan drug designation for advanced melanoma treatment

• Vitiligo and dementia: Is there a connection?

Jan. 20, 2021:

• Natural supplements in dermatology: What drugs do they interact with?

• DermWorld Insights and Inquiries: Olmsted syndrome patients can finally put their foot down

• Derm Coding Consult: UnitedHealthcare delays Laboratory Test Registry until 2022

• Vaccinating patients on TNF inhibitors

• FDA’s Bad Ad Program offers CME opportunity

• Academy Advisory Board invites members to submit policy resolutions

Jan. 13, 2021:

• CMS implements congressionally mandated adjustments, avoiding steep Medicare cuts

• DermWorld Insights and Inquiries: Not aging like fine wine — The myths and mysteries of acquired port wine stains

• PPP loan forgiveness 101

• How should dermatologists decide which patients get in-person appointments during a pandemic?

• Have stretch marks finally met a worthy foe?

• COVID-19 public health emergency extended

Jan. 6, 2021:

• Managing pain in hidradenitis suppurativa patients: A proposed algorithm

• DermWorld Insights and Inquiries: Itching to see if polymerase chain reaction mite be the future of diagnosing scabies

• 2021 E/M guidance sunscreen update

• Does exercise affect papulopustular acne?

• COVID-19 Dermatology Registry accepting vaccine side effect submissions

• Academy seeks statements on proposed bylaws amendments

Dec. 23, 2020:

• The impact of COVID-19 on the practice of dermatology

• DermWorld Insights and Inquiries: Holiday greeting 2020

• HHS announces additional Medicare relief funding

• FDA approves topical AK treatment

• Young Physician Focus: Bidding 2020 farewell (and good riddance!)

• Three cases of facial swelling reported in Moderna vaccine trial

• AAD members among Medscape’s 25 Rising Stars

• iPledge callers experience long wait times

Dec. 16, 2020:

• What are risk factors for frontal fibrosing alopecia?

• DermWorld Insights and Inquiries: We’re in hot water! Vibrio vulnificus infections are heading north.

• Anti-kickback statute implications for company-speaker programs

• Information blocking rule: What does it mean?

• Academy seeks statements on proposed bylaws amendments

• FDA shares voluntary topical drug product recall

Dec. 9, 2020:

• What are the effects of OTC moisturizers on skin barrier function?

• DermWorld Insights and Inquiries: Much ado about nothing in dermatopathology

• CMS fails to prevent Medicare cuts, E/M payment changes move forward

• ABMS Draft Standards for Continuing Certification Call for Comments delayed until April 2021

• Participate in the COVID-19 Dermatology Registry

• Academy seeks assistant secretary-treasurer nominees

• Deadline extended for MIPS extreme and uncontrollable circumstances application

Dec. 2, 2020:

• Surgical vs non-surgical interventions for basal cell carcinoma

• DermWorld Insights and Inquiries: Pigmented onychomatricoma — Avoid getting nailed by misdiagnosis

• Derm Coding Consult: Coding for preventive skin examination in 2021 and beyond

• MIPS dates and deadlines: What you need to know

• How thoroughly are biosimilar products tested?

• Hurricane Laura, wildfires qualify as national disasters, receive neutral payment adjustment

Nov. 18, 2020:

• Hydrogen peroxide and the common wart: Phase 2 results are in

• DermWorld Insights and Inquiries: Granulomatous slack skin — More than one type of mimicry

• FDA loosens restrictions on compounding in physician offices

• DermWorld Young Physician Focus: You are what you consume

• Deadline for MIPS extreme and uncontrollable circumstances application approaching

• FDA releases microneedling device guidance

Nov. 11, 2020:

• How effective are steroid-sparing agents in treating chronic alopecia areata?

• DermWorld Insights and Inquiries: Raising a toast to advances in treating alcohol-induced flushing

• Derm Coding Consult: Coding for office visit evaluation and management (E/M) in 2021 and beyond: FAQs

• FBI warns of cybercrime threat to health care providers, hospitals

• Can dermoscopy be used to evaluate skin barrier repair?

• Academy seeks assistant secretary-treasurer nominees

Nov. 4, 2020:

• FDA approves OTC head lice lotion

• DermWorld Insights and Inquiries: Striving to alleviate the physical and emotional scars of central centrifugal cicatricial alopecia

• The future of telehealth

• New EHR interoperability rule delayed

• Derm Coding Consult: Payers to reinstate cost-sharing requirements for virtual appointments

• Rejected VA claims can now be appealed

• FDA, UMD seek feedback on compounded drug use

Oct. 28, 2020:

• Drug may offer prolonged improvement in chronic spontaneous urticaria

• DermWorld Insights and Inquiries: Looking into the whites of the mouth

• Why will dermatology experience a 2% payment reduction in 2021?

• Young Physician Focus: Help wanted

• Derm Coding Consult: Updated NCCI edits now available

Oct. 21, 2020:

• Can medical scribes boost physician profits?

• DermWorld Insights and Inquiries: Can topical ketoconazole tip the scales for acne vulgaris?

• Providing equitable dermatologic care for people with disabilities

• Got a story to tell? Share it in DermWorld!

• E/M coding for 2021: Major changes ahead

• FDA, UMD seek feedback on compounded drug use

Oct. 14, 2020:

• OTC scar treatments: What does the evidence say about efficacy?

• DermWorld Insights and Inquiries: Studying skin aging never gets old — The potential role of oxytocin

• Medicare advance payment program receives repayment extension

• Virtual group election period open for MIPS 2021

• Reducing pain, anxiety for dermatologic procedures using local anesthesia

• FDA, UMD seek feedback on compounded drug use

Oct. 7, 2020:

• The costs of prior authorizations in a dermatology department

• DermWorld Insights and Inquiries: Targeted anti-complement therapy may prove to be a complementary treatment for bullous pemphigoid

• Derm Coding Consult: CMS modifies the 60-day limit for locum tenens during COVID-19

• California Governor signs nurse practitioner independent practice law

• Can COVID-19 be transmitted via wounded skin?

• HHS announces new provider relief payments

• Academy seeks assistant secretary-treasurer nominees

Sept. 30, 2020:

• Private equity in dermatology, health care grows

• DermWorld Insights and Inquiries: New data to recall when considering radiation recall dermatitis

• Young Physician Focus: Prepping for round two

• Practicing cosmetic dermatology during COVID-19

• FDA, UMD seek feedback on compounded drug use

• FDA rule allows drug importation from Canada to lower drug prices

Sept. 23, 2020:

• Nail manifestation and COVID-19: The red half-moon sign

• DermWorld Insights and Inquiries: The profound dermatologic manifestations of COVID-19: Part VII — Who was that masked man?

• Derm Coding Consult: E/M utilization in dermatology

• Dermatology resident develops face masks from recycled medical supplies

• Therapeutic potential of cannabinoid-based therapy in dermatology

Sept. 16, 2020:

• Patients who won’t wear a mask: Avoiding a lawsuit

• DermWorld Insights and Inquiries: Slammed by slime

• Derm Coding Consult: New CPT code 99072 for COVID-19 PPE

• Pharmacists can vaccinate kids under latest guidance

• Got a story to tell? Share it in DermWorld!

• FDA, UMD seek feedback on compounded drug use

Sept. 9, 2020:

• What are the cutaneous side effects associated with drugs prescribed for COVID-19?

• DermWorld Insights and Inquiries: Mentorship mentation — Bringing out the best of us!

• Derm Coding Consult: CMS resumes medical claim review audits

• NYT publishes Academy’s response to skin of color article

• Participate in MIPS cost measure field testing

• Academy seeks assistant secretary-treasurer nominees

Sept. 2, 2020:

• What role can dermatologists play in developing a COVID-19 vaccine?

• DW Insights and Inquiries: Dermatopathology’s taste of honey

• Non-discrimination protections change under ACA

• Skin of color dermatology content on Instagram

• Submit nominations for 2021 Academy election

Aug. 26, 2020:

• Navigating immunosuppression during a pandemic: A guide for the dermatologist

• DW Insights and Inquiries: Topical tacrolimus topics

• Derm Coding Consult: Proposed Medicare fee schedule includes telehealth, E/M coding updates

• Young Physician Focus: Don’t waste a good crisis

• Participate in MIPS cost measure field testing

Aug. 19, 2020:

• Does topical tacrolimus for AD increase cancer incidence in children? Study says ‘no.’

• DW Insights and Inquiries: Juvenile lichen sclerosus — A loss of innocence

• Derm Coding Consult: Watch out for MIPS 2019 overpayment and recoupment notification

• Derm Coding Consult: Streamlining the claim denial process in your practice

• AAD and NPF release psoriasis guidelines on topical treatments

• Participate in MIPS cost measure field testing

Aug. 12, 2020:

• Treating trichotillomania: Beyond antidepressants

• DW Insights and Inquiries: Mogamulizumab for CTCL — Targeted therapy and immunotherapy crossing paths

• 2021 Medicare fee schedule rewards cognitive work, but cuts procedures

• Executive Order on improving rural health, telehealth access

• Dermal absorption of topical drugs

• Academy seeks assistant secretary-treasurer nominees

Aug. 5, 2020:

• COVID-19 and employed physicians: Contracts, furloughs, and termination

• DW Insights and Inquiries: Unmasking the complications of personal protective equipment

• AAD-NPF release psoriasis guidelines on topical treatments

• Participate in MIPS cost measure field testing

• Keeping the frontline workers safe

• HHS extends CARES Act Provider Relief Fund application deadline to Aug. 28

• Submit nominations for the 2021 Academy election

July 29, 2020:

• COVID-19: The impact on employed dermatologists

• DW Insights and Inquiries: The profound dermatological manifestations of COVID-19 part VI — Going to the dogs

• Young Physician Focus: When it rains, it pours

• Dermatologic concerns for transgender patients

• Dermatology drive-thru during COVID-19

July 22, 2020:

• AK draft guidelines released: Submit your comments

• DW Insights and Inquiries: Why you should hear about the red ear syndrome

• Proposed 2021 Medicare changes: What should dermatologists expect?

• Topical resorcinol as long-term treatment of mild to moderate hidradenitis suppurativa

• Got a story to tell?

• On the front lines in Boston

• Academy seeks assistant secretary-treasurer nominees

• Register for HHS Telemedicine Hack

July 15, 2020:

• JAAD study demonstrates direct link between chilblains and COVID-19

• DW Insights and Inquiries: Incysting on understanding pilar cysts

• Derm Coding Consult: Practical applications of 2021 E/M coding changes

• AAD seeks member comments for AK guidelines

• Caring for their own

• Submit nominations for 2021 Academy election

July 8, 2020:

• Chilblains and COVID-19: Is there an association?

• DW Insights and Inquiries: Et tu, ibrutinib?

• How to treat nail lichen planus during the COVID-19 pandemic

• CMS publishes 2019 Open Payments data

• Being there

• FDA, M-CERSI to host virtual workshop on topical drug development

• Paycheck Protection Program deadline extended to Aug. 8

July 1, 2020:

• Derm Coding Consult: E/M coding — What has changed?

• DW Insights and Inquiries: Spironolactone — An increasingly recognized hero in acne therapy

• Is it ethical to charge patients an infection control fee?

• On the front lines in Connecticut

• CMS announces relief for 2020 MIPS participants

• Academy seeks assistant secretary-treasurer nominees

June 24, 2020:

• Derm Coding Consult: Are you ready for E/M coding changes?

• DW Insights and Inquiries: Phacing the future — When patients with PHACE syndrome grow up

• You’re not alone: AAD survey reveals significant impact of COVID-19 on dermatology practices

• Pride 2020: What is the meaning of Pride and how exactly should it impact our practice?

• Young Physician Focus: The power of collaboration

• ECHO on the front lines of COVID-19

June 17, 2020:

• Treating patients during the COVID-19 pandemic? Here’s how to minimize your malpractice liability risk.

• DW Insights and Inquiries: Researching therapeutic reformation of the capillary malformation — Arteriovenous malformation syndrome

• AADA successfully advocates against unfair Medicare prior authorization policy

• Derm Coding Consult: New interactive evaluation and management resource tool available

• How does race impact time to treatment for melanoma?

• Reflections from a dermatologist on a COVID-19 medical ward

• CMS issues final rule on advancing interoperability, patient access to health data

• Academy Advisory Board invites members to submit policy resolutions

June 10, 2020:

• Where is teledermatology most useful? Patient web searches may provide clues.

• DW Insights and Inquiries: Lichenoid and granulomatous dermatitis — Points to ponder

• During the COVID-19 pandemic, ‘Leaders eat last.’

• Two more days…there’s still time to register for AAD VMX

• Submit nominations for 2021 Academy election

June 3, 2020:

• COVID-19 and androgenetic alopecia: Is there a link?

• DW Insights and Inquiries: Clear cell papulosis — Clearly distinctive, clearly underrecognized

• Register for the Academy’s virtual meeting experience, AAD VMX

• COVID-19 dermatology registry qualifies as an Improvement Activity

• Academy seeks assistant secretary-treasurer

• COVID-19 skin care and hygiene kits for the homeless

• Academy Advisory Board invites members to submit policy resolutions

May 27, 2020:

• How to classify COVID-19 rashes

• DW Insights and Inquiries: On the cusp of extraordinary advances in extramammary Paget disease

• Derm Coding Consult: Telephone code Medicare reimbursement will be updated automatically

• Register for the Academy’s virtual meeting experience, AAD VMX

• Young Physician Focus – Teledermatology: Love it or list it?

• Stay tuned: New E/M codes

• From distilleries to the State House: Garnering support during COVID-19

May 20, 2020:

• COVID-19 and physician compensation: Survey shows likely decline

• DW Insights and Inquiries: Reopening the dermatologic surgery office in the COVID-19 era

• Register for the Academy’s virtual meeting experience, AAD VMX

• Race, equity, and the impact of COVID-19 on African Americans

• Tell Congress how COVID-19 is affecting your practice and patients

May 13, 2020:

• Caring for older patients during COVID-19? What you need to know.

• DW Insights and Inquiries: The profound dermatological manifestations of COVID-19: Part V – Pediatric multisystem inflammatory syndrome

• Register for the Academy’s virtual meeting experience, AAD VMX

• E/M changes on the horizon

• “It wasn’t a choice. It was a responsibility.”

• FDA approves new hyaluronic acid lip filler

• Derm Coding Consult: CMS clarifies telehealth and telephone coding during COVID-19

May 6, 2020:

• What dermatologic hazards are COVID-19 health care workers facing?

• DW Insights and Inquiries: Working up pernio — How far should you dip your toe in the water?

• Novel topical acne treatment appears to be effective

• Emergency supply drive for front line COVID-19 workers

• National Academy of Sciences elects Angela M. Christiano, PhD

• First open-access papers published in JAAD International

April 29, 2020:

• Derm Coding Consult answers COVID-19 telehealth coding FAQs

• DW Insights and Inquiries: Here comes summer (and sunscreen conversations)!

• Congress passes legislation to provide further COVID-19 relief funding

• HHS agencies delay new EHR interoperability rules

• Academy encourages participation in new COVID-19 dermatology registry

April 22, 2020:

• Are you exempt from the COVID-19 FMLA and paid sick leave provisions?

• DW Insights and Inquiries: The profound dermatological manifestations of COVID-19: Part IV - Cutaneous features

• Patients warming to telehealth as an option for care

• More than 9,000 health care workers infected with coronavirus

• Academy encourages participation in COVID-19 dermatology registry

April 15, 2020:

• Derm Coding Consult: Telehealth coding, documentation, and reimbursement during COVID-19: What you need to know.

• DW Insights and Inquiries: The H syndrome – Understanding Y

• Academy encourages participation in COVID-19 registry

• On the front lines of COVID-19

• Hundreds of thousands of health care workers face layoffs, furloughs during pandemic

• Medical students may frequently misdiagnose dermatologic disorders in skin of color patients

• Join the Academy’s skin cancer measure testing project:

April 8, 2020:

• Employers’ legal responsibilities during COVID-19: What you need to know.

• DW Insights and Inquiries: The profound dermatologic manifestations of COVID-19: Part III

• ABD relaxes 2020 MOC requirements

• Academy election results announced

• Pilot study examines hydroxychloroquine for COVID-19

• Social distancing = social learning

April 1, 2020:

• What to do with iPLEDGE patients during COVID-19

• DW Insights and Inquiries: Knuckling down on knuckle pads

• Medicare offers physicians advance payments to address COVID-19 cash-flow issues

• FDA approves crisaborole for AD patients as young as three months

• Derm Coding Consult: Guidance on using teledermatology during the COVID-19 pandemic

• Will ultrasound gel improve wart treatment efficacy?

• Virginia bans indoor tanning for minors under 18

• Join the Academy’s skin cancer measure testing project

• Cast your vote in the AAD election by April 4

March 25, 2020:

• CMS extends 2019 MIPS reporting deadline

• DW Insights and Inquiries: The profound dermatologic manifestations of COVID-19 – Part 2

• Young Physician Focus: A legitimate concern

• COVID-19 pandemic drains hydroxychloroquine supply

• Join the Academy’s skin cancer measure testing project

• FDA, M-CERSI to host virtual workshop on dermal absorption of topicals

• From COVID-19 to private equity, candidates weigh in on timely issues

March 18, 2020:

• CMS offers physicians flexibility during COVID-19 emergency

• DW Insights and Inquiries: The profound dermatological manifestations of COVID-19

• Feedback requested: AAD/NPF draft guidelines for the management and treatment of psoriasis with topical therapy, complementary and alternative medicine modalities for psoriasis severity measures

• HHS agencies announce new EHR interoperability rules

• Coming soon: Cast your vote in the AAD election

March 11, 2020:

• A guide to managing coronavirus in dermatology clinics

• DW Insights and Inquiries: The 2020 vision for nemolizumab in atopic dermatitis

• Feedback requested: AAD/NPF draft guidelines for the management and treatment of psoriasis with topical therapy, complementary and alternative medicine modalities for psoriasis severity measures

• Brand-name prescription drug prices up 159% since 2007

• JAAD research finds new link between vitiligo and autoimmune diseases

• Here’s your chance to get to know the 2020 AAD Election candidates

March 4, 2020:

• Academy and NPF release new psoriasis guidelines on systemic therapies

• DW Insights and Inquiries: Anterolateral leg alopecia

• Choose a Dermatologist: Participate in the AAD’s new social media campaign

• Amid coronavirus outbreak, FDA takes steps to ensure quality of imported products

• Insurers offering health care services?

• Coming soon: Cast your vote in the AAD election

• Election coverage you don’t want to miss

Feb. 26, 2020:

• Plantar warts: Shave with PDT or cryotherapy?

• DW Insights and Inquiries: A niche with NICH

• Legislators seek to expand sunscreen ingredient ban

• Young Physician Focus: Giving back

• Novitas starts Mohs surgery audits

• Pharmaceutical executive pleads guilty to generic price fixing

• Just Announced: Meet the AAD 2020 candidates

• Derm World apologizes for logo use in outside advertising

Feb. 19, 2020:

• Study raises concerns about skin cancer detection apps

• DW Insights and Inquiries: Men in the twilight Zoon

• STD medical claims in the U.S. soar

• Does tobacco exposure increase risk of pediatric psoriasis?

• More than 20% of surgery patients have received surprise medical bills

• Get ready for the 2020 Academy elections

Feb. 12, 2020:

• FDA prioritizes drug shortages with new approval policy

• DW Insights and Inquiries: Twenty years of imiquimod taking its toll on lentigo maligna: Where are we?

• CMS updates MIPS Explore Measures Tool for 2020

• Derm Coding Consult: AMA CPT releases new online digital E/M services codes for private payers

• What are the hazardous effects of e-cigarettes on the skin?

• President Trump declares public health emergency over coronavirus

• Is nadolol a safe option for infantile hemangioma?

Feb. 5, 2020:

• Legislators aim to prevent sunscreen bans

• DW Insights and Inquiries: Prurigo pigmentosa as the “keto rash”: I’m a believer

• Correction issued to pediatric psoriasis treatment guidelines

• FDA grants priority review of dupilumab for children

• Pemphigus vulgaris therapy granted FDA orphan drug status

• Presentation of evidence on the HPV vaccination

Jan. 29, 2020:

• Patients are using YouTube to get information on isotretinoin. Here’s what you need to know.

• DW Insights and Inquiries: Getting steamed over vaping

• Derm Coding Consult: A New Year’s reminder on preventive services

• Are your patients at risk? Potent topical corticosteroids sold OTC

• The whole dermatologist: Beyond the skin

• How do physicians run for office? The AMA’s workshop will guide you.

• 2020 QPP resources available in the Resource Library

Jan. 22, 2020:

• Academy comments on FDA sunscreen study

• DW Insights and Inquiries: Paradoxical biological reactions and Grandma Dora’s waterbed

• 2020 kicks off with revised ICR coding guidelines

• Participate in MGMA's 2020 Compensation and Production Survey

• Video education, simulation improves surgical training among dermatology residents

Jan. 15, 2020:

• Which cosmeceuticals have proven clinical efficacy?

• DW Insights and Inquiries: Thoughts on hyaluronidase and The House of God

• Cancer death rate falls by largest one-year drop on record

• How do physicians run for office? The AMA’s workshop will guide you.

• Check your 2020 MIPS eligibility

Jan. 8, 2020:

• FDA’s biotin warning: Was it enough to educate physicians, patients about the risks?

• DW Insights and Inquiries: Dupilumab’s growing pains

• 2020 kicks off with revised ICR coding guidelines

• Join the Academy’s skin cancer measure testing project

• FDA warns about respiratory problems with gabapentin

• 2019 MIPS data submission period is open

Dec. 18, 2019:

• Which physicians were sued most in 2019?

• DW Insights and Inquiries: Holiday greeting 2020 — eyeing dermatology’s future

• New DW Academy Insider coming in 2020

• Does teledermatology improve PCP-delivered care for disadvantaged patients?

• Learning to fail

• Senate confirms Hahn to lead the FDA

• Virtual group election period open for MIPS 2020 performance period

Dec. 11, 2019:

• Physician depression increases medical errors…increasing depression

• DW Insights and Inquiries: Topical retinoid therapy for acanthosis nigricans — in the thick of it

• MIPS: What you need to know now — and what’s ahead

• Leveraging virtual networks to improve dermatologic access and care

• Why are females less satisfied with biologic treatments for psoriasis?

• New Medicare card transition period ending

Dec. 4, 2019:

• New opioid prescribing guidelines for dermatologic procedures

• DW Insights and Inquiries: Beware — discordance abounds among pathologists in the diagnosis of melanocytic neoplasms

• Prepare for next month’s intermediate and complex repair coding guidelines updates

• 2019 AMA House of Delegates Meeting: Regulation of PAs, board certification standards, and more

Nov. 20, 2019:

• Which types of dermal fillers are associated with increased complications?

• DW Insights and Inquiries: Rituximab and dermatomyositis — Dr. Samitz would be proud

• An ode to the good old days

• CMS issues final and proposed rules to increase price transparency

• Dermatologists bridge gaps in rural care access

• Join the Academy’s skin cancer measure testing project

• Virtual group election period open for MIPS 2020 performance period

Nov. 13, 2019:

• New recommendations for detecting noninvasive melanoma published

• DW Insights and Inquiries: The naked truth about total body skin examination — A lesson from Goldilocks and the Three Bears

• Apply or nominate a colleague for Advocate of the Year

• Health Affairs highlights dermatologist voices in new series

• New Medicare card transition period ending

• MIPS extreme and uncontrollable circumstances policy expands to new areas

Nov. 6, 2019:

• SPF 50+ vs. 100+ — is there a difference?

• DW Insights and Inquiries: Getting the gist of GIST cutaneous hyperpigmentation disease

• Academy announces new Executive Director and CEO

• Academy releases joint guidelines for psoriasis in pediatric patients

• AAD/A members vote to remove Board member

• Join the Academy’s Skin Cancer Measure Testing Project

• Federal report addresses drug shortage causes, potential solutions

October 30, 2019:

• Potential treatment for chronic urticaria may offer complete control

• DW Insights and Inquiries: Can chowing down improve pseudoxanthoma elasticum?

• Advances in medical technology: friend or foe?

• Do U.S. dermatology residents suffer from imposter syndrome?

• Syphilis and STDs on the rise for fifth year in a row

October 23, 2019:

• Treating molluscum contagiosum: Ingenol mebutate vs. imiquimod

• DW Insights and Inquiries: Coming clean on bleach baths for atopic dermatitis

• Ancestry launches consumer genetic health testing

• CMS offers new MIPS resources

• Florida bill proposes requiring prescriptions for sunscreens that could harm coral reefs

• World Psoriasis Day is approaching

October 16, 2019:

• Is there a link between lupus and prescription opioids?

• DW Insights and Inquiries: Nonepidemic Kaposi sarcoma: The fifth dimension

• Academy cautions members of fraudulent email solicitations promoting sale of AAD’s Annual Meeting attendee list

• Updated AAD.org puts most-used content at members’ fingertips

• GAO interviews Academy experts on sunscreen safety testing

• New Medicare card transition period ending

• AAD diversity workshop addresses disparities in dermatology

October 9, 2019:

• Topical calcineurin inhibitors vs. topical corticosteroids for vitiligo

• DW Insights and Inquiries: Glucose monitors — Not as sweet as they seem

• American Board of Dermatology announces alternative to MOC exam

• Upcoming coding changes: Differentiating intermediate from complex repairs

• Academy supports legislation that would ensure patient access to medication

• Virtual group election period open for MIPS 2020 performance period

• President Trump executive order calls for sweeping changes to Medicare Advantage

October 2, 2019:

• Does gluten increase risk for psoriasis and AD in women?

• DW Insights and Inquiries: Cutting giant congenital nevi down to size molecularly

• Upcoming coding changes: Differentiating intermediate from complex repairs

• Apple cider vinegar soaks to treat AD: Yea or nay?

• Which dermatologic conditions have the highest hospital readmission rates...and what's the cost

September 25, 2019:

• Which biologics cause weight gain in psoriasis patients?

• DW Insights and Inquiries: I never wanted chaperones — until now

• Two sides to every story

• Academy's contribution to skin cancer prevention shows nationwide progress  

• Physician burnout is real, but AADA's DERM360 resources can help 

• Quinacrine dihydrochloride recalled by Darmerica

• Nominations sought for 2020 Academy election

September 18, 2019:

• HPV vaccine to treat common warts?

• DW Insights and Inquiries: Calcipotriene and 5-fluorouracil — Dermatology’s new dynamic duo?

• Government green-lights co-pay accumulator programs for 2020

• Howard Rogers, MD, testifies to House committee about prior authorization burdens

• Hurricane Barry triggers MIPS extreme and uncontrollable circumstances policy

• Medicare Beneficiary Identifier (MBI) transition period nearing its end

September 11, 2019:

• How often do dermatologists prescribe off-label medications?

• DW Insights and Inquiries: Shingles and the battle of the bulge

• Feedback requested: AAD/NPF draft guidelines for the management of psoriasis with non-biologics

• Deadline approaching to submit a 2018 MIPS targeted review request

• FDA expands approval of two topical psoriasis therapies to pediatric patients

• Grants available for technology-based teaching applications

September 4, 2019: 

• New Drug Application submitted for rosacea topical treatment

• DW Insights and Inquiries: Parabens — A common allergen with lots of hype and no real harm

• Feedback requested: AAD/NPF draft guidelines for the management of psoriasis with non-biologics

• AAD media coverage on sun protection earns one billion media impressions

• Nominations sought for 2020 Academy election

August 28, 2019:

• Dupilumab shows positive results for younger atopic dermatitis patients

• DW Insights and Inquiries: Finding joy in pediatric phototherapy

• FDA, UMD seek feedback on compounded drug use

• California, New York ban discrimination against natural hair

• Grants available for technology-based teaching applications

August 21, 2019:

• FDA grants breakthrough therapy designation to advanced melanoma treatment

• DW Insights and Inquiries: Rejecting preconceived notions of squamous cell carcinomas in patients experiencing transplant rejections

• Quality Payment Program hardship exemption applications now available

• New hidradenitis suppurativa guidelines highlight disease complexity

• Submit an abstract for the Gross and Microscopic Symposium

August 14, 2019:

• CMS seeks to reduce prior authorization burden on physicians

• DW Insights and Inquiries: Putting muscle into isotretinoin laboratory testing isn’t chopped liver!

• Applicants sought for research excellence awards for young dermatology investigators

• Medicare Beneficiary Identifier (MBI) transition period nearing its end

• Nominations sought for 2020 Academy election

August 7, 2019:

• What effect has iPLEDGE had on pregnancy rates?

• DW Insights and Inquiries: Snitching on Schnitzler syndrome — The continuing search for an optimal biomarker

• U.S. Virgin Islands bans sunscreen with oxybenzone and octinoxate

• Joint clinical guidelines provide evidence-based practices for treating psoriasis 

• Submit an abstract for the Gross and Microscopic Symposium

July 31, 2019:

•  Academy and NPF release new psoriasis phototherapy guidelines

• DW Insights and Inquiries: A metabolic pathway that may allow dermatologists to run rings around porokeratoses

• Having trouble finding diphenylcyclopropenone?

• Submit an abstract for the Gross and Microscopic Symposium

• Nominations sought for 2020 Academy election

July 24, 2019:

• Wound care after dermatologic procedures lacks uniformity

• DW Insights and Inquiries: Eosinophilic dermatosis of hematologic malignancy: Reality bites

• A look back at dermatology’s past with an eye on the future

• A customized vaccine for advanced melanoma?

• Call for nominations for 2020 AAD election

• House votes to repeal ‘Cadillac Tax’

• Sheila F. Friedlander, MD, to present on dermal absorption at Univ. of Maryland School of Pharmacy workshop

July 17, 2019:

• Isotretinoin, depression, and suicide: What’s the connection?

• DW Insights and Inquiries: Should dermatologists be anti-antihistamine for atopic dermatitis?

• 2018 MIPS performance feedback, final score, and targeted review now available

• Natural skin care regimen vs. synthetic regimen for managing rosacea

• Two more speakers confirmed for 2019 AADA Legislative Conference

July 10, 2019:

• FDA clears new body sculpting device

• DW Insights and Inquiries: The pachydermoperiostosis prostaglandin paradigm

• Increase in demand triggers shortage of intravenous immunoglobulin

• Patient Access Hero: Dallas clinic provides free multidisciplinary care

• Miami Beach Commission Sustainability and Resiliency Committee rejects sunscreen ingredient ban

July 3, 2019:

• Academy comments on FDA sunscreen proposal

• DW Insights and Inquiries: Oy, another “Oid” to worry about — cryptococcoid lesions

• VA launches Community Care Network to provide better access to care

• CMS has begun MIPS data validation, audits for 2017 and 2018 performance years

• What happened at the AMA House of Delegates meeting? Private equity, compounding, and more.

• CMS proposes Medicare Part D electronic prior authorization standards

June 26, 2019:

• CMS/NCCI changes to PTP edits go into effect next week

• DW Insights and Inquiries: Conceptualizing atypical fibroxanthomas, pleomorphic dermal sarcomas, and undifferentiated pleomorphic dermal sarcomas

• Beyond the specialty: How AccessDerm helps primary care providers

• How do melanoma patients view skin self-examinations?

• Delaware governor signs critical step therapy bill

June 19, 2019:

• Do hidradenitis suppurativa patients have a greater comorbidity burden than psoriasis patients?

• DW Insights and Inquiries: The newest frontier for biologics and psoriasis may be adherence

• Complimentary webinar: FDA's proposed sunscreen rule — what safety data is the FDA looking for and why?

• Private equity by the numbers

• Media personality Michael Smerconish will offer keynote at 2019 AADA Legislative Conference

• 2020 committee appointment application now open

June 12, 2019:

• A new way to treat warts? Heat may be the answer.

• DW Insights and Inquiries: Taking the challenge: Social media, adolescents, and the skin

• Dollars and cents: What’s the cost of physician burnout?

• CMS seeks input for reducing administrative, regulatory burdens

June 5, 2019:

•  Self-injection of black market dermal fillers poses health concern

• DW Insights and Inquiries: Stress² + Hormones² = Acne²

• CMS/NCCI announce changes to PTP edits

• New survey highlights impact of local anesthetics shortage

• FDA approves first treatment for graft versus host disease

• What’s the direct liability for business associates under HIPAA?

• 2020 committee appointment application now open

   

May 29, 2019:

• Academy issues statement on sunscreen safety

• DW Insights and Inquiries: Life is just a bowl of cherry angiomas

• AccessDerm: Serving the underserved

• Anthem enforces modifier 25 denials

• New resolution paves the way for sunscreen in schools and sun-safe education for kids

• Kaposi sarcoma treatment gets Breakthrough Therapy designation

• Patient Care Hero: Could a skin rash provide a clue to this woman’s diagnosis

• Academy Advisory Board invites members to submit policy resolutions

May 22, 2019:

• What's happening to practice ownership?

• DW Insights and Inquiries: Breaking the terbinafine laboratory habit for onychomycosis

• Do you know how to get to 30 points to avoid a MIPS penalty?

• Augmented intelligence: The synergy of man and machine to improve patient care

• Maryland passes under-18 indoor tanning ban

• CMS takes action to lower prescription drug prices, increase transparency

May 15, 2019:

• Why are psoriasis patients turning to complementary and alternative medicine?

• DW Insights and Inquiries: Coughing up a new warning for ustekinumab

• AAD adopts position statement on sexual and gender minority health

• HHS finalizes rule requiring drug prices to be disclosed in TV ads

• A cheat sheet to dermatology’s ‘hidden curriculum’ 

• Dr. Resneck testifies to Congress about drug prices and prior authorization

• Register for the 2019 AADA Legislative Conference 

• Academy Advisory Board invites members to submit policy resolutions

May 8, 2019:

• Skin scratching and intestinal changes: What’s the link?

• DW Insights and Inquiries: Progress for progressive multifocal leukoencephalopathy

• New maximum penalties for HIPAA violations

• Adopt-a-Shade: Working together

• Teledermatology templates decrease face-to-face referrals

May 1, 2019:

• FDA approves risankizumab for treatment of plaque psoriasis

• DW Insights and Inquiries: When assessing morbilliform eruptions think about morbilli (measles)!

• We want your feedback: Draft psoriasis guidelines for pediatric patients

• CMS to allow insurers to adopt copay accumulators

• 3 ways to promote skin cancer awareness this month

• Preliminary MIPS performance data now available

• Members of Congress take on sunscreen use

• NIH to honor dermatologist Stephen I. Katz, MD, PhD, on May 3

• 2020 committee appointment application now open

April 24, 2019:

• Dermal filler may effectively treat facial acne scarring

• DW Insights and Inquiries: Fever, rash, and lymphadenopathy may be wearing more than one DRESS

• AAD Board of Directors shed light on the strategic plan’s impact on members

• Feedback requested: Draft psoriasis guidelines for pediatric patients

• Deadline to review QPP performance data April 27

• 2020 committee appointment application now open

April 17, 2019:

• Having trouble accessing compounded quinacrine tablets? Here’s why.

• DW Insights and Inquiries: A ‘pregnant pause’ is necessary before concluding on the obstetric risk of vitiligo

• Lessons learned from the customer service world

• Let’s talk about leading care teams and other elephants in the room

• Who are the happiest dermatologists? New survey results have answers.

• NIH to honor dermatologist Stephen I. Katz, MD, PhD, on May 3

• Academy committee volunteers need to update their disclosures

April 10, 2019:

•  ‘Inactive’ ingredients in pills may cause allergic reaction

• DW Insights and Inquiries: Is there a best approach to widespread actinic keratoses?

• What’s the optimal way to perform total body skin examinations?

• Study shows medical spa oversight needs improvement

• Deadline to review QPP performance data April 27

April 3, 2019: 

• Can the elimination diet hurt pediatric atopic dermatitis patients?

• DW Insights and Inquiries: Tofacitinib – a JAK inhibitor of all trades

• Unity in dermatology starts with putting patients first 

• Acne risk in transgender men treated with testosterone

• Ixekizumab sustains plaque psoriasis improvements, quality of life for one year

• American Academy of Dermatology announces Interim Executive Director

March 27, 2019: 

• Academy forms task force to address FDA proposed rule on sunscreen monograph, ingredients

• DW Insights and Inquiries: Biting my nails worrying about atypical presentations of nail unit melanomas

• Real-time patient data transforms the practice and improves care

• Joint position statement educates policymakers on safe in-office preparation of buffered lidocaine by dermatologists

• Patient Care Heroes: Carrie Kovarik, MD, and Keith Hamilton, MD

March 20, 2019:

• Sodium bicarbonate injection recalled due to presence of glass

• DW Insights and Inquiries: Dermatologists will increasingly meet mammalian meat allergy

• Diversifying the specialty can result in high-quality access to dermatologic care

•  Trouble getting off-label meds? Flawed compendia causing coverage denials for dermatologic conditions

• Miami Beach commissioners vote ‘no’ on sunscreen ingredient prohibition

March 13, 2019:

• Is routine laboratory monitoring for isotretinoin patients necessary?

• Welcome to Dermatology World Insights and Inquiries

• Innovative learning experiences equip members to provide compassionate patient care

• Scientists report curing HIV-positive patient for a second time

• Hidradenitis suppurativa linked to cardiovascular disease

•  FDA statement discusses plan for naming biological medicines

March 6, 2019:

• FDA approves self-injection of guselkumab for plaque psoriasis 

• Nearly 80% of public find drug prices 'unreasonable'

• Biotin supplementation unnecessary for most patients, may lead to misdiagnosis

• Why are academic dermatologists burned out?

February 27, 2019:

• FDA approves new neurotoxin for frown lines

• Breaking down the FDA’s new sunscreen proposal 

• Update on Anthem instituting new modifier 25 payment policy

• A new way to help diagnose allergic versus irritant contact dermatitis

• Dermatologists concerned over use of equine medicine to treat rosacea

• AAD and NPF release new guideline for treatment of psoriasis with biologics

• Skin biopsy rate: An assessment of provider utilization

February 20, 2019:

• Biologics may help fight heart disease in psoriasis patients

• AAD mourns the passing of Richard L. Dobson, MD

• Feedback requested: AAD joint guideline for reconstruction after skin cancer resection

• Severe atopic dermatitis guidelines developed

• Private payer issues with new biopsy codes

• Tool may help predict melanoma recurrence after negative SNB

• View candidates and ballot book online

February 13, 2019:

• Do biologics have more adverse events than conventional therapies? Researchers say 'No.'

• AAD Strategic Plan driven by member feedback

• Feedback requested: AAD/ASPS joint guideline for reconstruction after skin cancer resection

• Medicare Administrative Contractors (MACs) deny Mohs with IHC claims

• Academy leaders convene on Capitol Hill for first Academy Leadership Day

• How much does having atopic dermatitis cost patients?

• 2019 AAD Election ballot packet moved online

February 6, 2019: 

• Nearly half of U.S. physicians are burned out

• AAD/A CEO announces departure this spring

• Anthem to institute new modifier 25 payment policy

• Researchers create new protein that may help cancer patients

• HHS proposes to end PBM rebate protections

• Who has access to dermatology services?

• NCCI and CMS address modifier 59 issues

• 2019 AAD Election ballot packet moved online

January 30, 2019:

• Dermatologists prescribe fewer antibiotics overall, but use increased with surgery

• CMS updates Open Payments data

• What causes allergic responses in patients with atopic dermatitis?

• YouTube videos about psoriasis biologics

• Is a new type of treatment for alopecia on the horizon?

• Palmetto GBA Jurisdiction J and M LCD #33445 affecting dermatology practices in several states

January 23, 2019:

• How does skin age? Researchers may have found the answer.

• AAD refutes misleading sunscreen article

• Taking the pain out of prior authorization denials

• Academy responds to Vision for the Future Commission draft report

• NCCI and CMS address modifier 59 issues

• Virginia Board of Medicine audits compounding practices

• 2019 AAD Election ballot packet moved online 

January 16, 2019:

• Isotretinoin may change bacteria levels on skin of acne patients

• Using DataDerm™ to seamlessly report for MIPS

• We want your feedback: Psoriasis draft guidelines

• Cochrane collection gathers new diagnostic test accuracy reviews for skin cancer

• New guideline available for infantile hemangioma treatment

• It’s time to use the new biopsy codes: Do you know how to use them?

• Remembering Stephen I. Katz, MD, PhD

• Academy Advisory Board invites members to submit policy resolutions

January 9, 2019:

• Smartphone app improves treatment adherence for psoriasis patients

• AAD mourns the passing of Stephen I. Katz, MD, PhD

• Submit your comments on psoriasis draft guidelines

• The Academy kicks off 2019 with a new Strategic Plan

• Increased competition causes falling prices for infliximab and biosimilars

• 2019 AAD Election ballot packet moved online

• 2018 MIPS data submission period now open

December 19, 2018:

• A new frown line treatment – coming soon?

• The AAD 2019 Strategic Plan: Our vision for the future

• December Heroes: Jean Pierre Galliani, MD, and Naomi Johansen, MD

• New guidelines issued for treating psoriatic arthritis

• It’s almost time to use the new biopsy codes: Do you know to use them?   

December 12, 2018:

• Trouble prescribing isotretinoin to new patients?

• New tax bill would repeal indoor tanning tax

• Are you smarter than DataDerm?™

• Apply for the AAD’s Cochrane Scholarship

• Academy Advisory Board invites members to submit policy resolutions

• Keep dermatology’s voice strong: Join the AMA

December 5, 2018:

• USP update on access to buffered lidocaine

• Are you smarter than DataDerm™?

• What’s the latest on drug shortages?

• Identifying, treating rosacea in skin of color

• 2019 AAD Election ballot packet moved online

November 28, 2018:

• A biologic for adolescent AD patients: Coming soon?

• MIPS in 2019: Changes are coming

• CMS seeks to implement real-time drug pricing widgets

• Are you smarter than DataDerm™?

• FDA attempting to get out ahead of drug shortages

• Help the Academy keep dermatology’s voice strong: Join the AMA

• CMS conducting new survey on post-op visits in global surgical codes

November 14, 2018:

• 2019 Fee Schedule – You asked. DWW answers.

• November Patient Care Hero: Jessica Burgy, MD

• Are you smarter than DataDerm™?

• CMS conducting new survey on post-op visits in global surgical codes

• The MIPS results are in: How did participants perform in 2017?

• FDA wants to hear from consumers about allergens and cosmetics

• Dermatologist, pediatrician win congressional seats

November 7, 2018:

• Fee Schedule: How will your practice fare in 2019?

• Adopt-a-Shade: Giving kids a safe place to play

• Academy releases guidelines for melanoma treatment

• Are you smarter than DataDerm?

• New psoriasis biologic now available in the United States

• FDA to ban lead from hair products

October 31, 2018:

• Oral antibiotic gets FDA approval for acne

• Teamwork Hero: Steven Daveluy, MD

• ABMS approves Micrographic Dermatologic Surgery subspecialty

• Are you smarter than DataDerm?

• Trump administration announces plans to lower drug costs

• Study: Topical tranexamic acid may be effective for erythematotelangiectatic rosacea

• Older adults opt for fewer medications

October 24, 2018:

• Drug shortages affecting your patients? Tell the FDA.

• When dealing with payers, the data can speak for itself

• Are you smarter than DataDerm™?

• Adalimumab biosimilar launches in 28 countries

• President Trump signs legislation prohibiting gag clauses

• HHS calls for drug prices in television ads

October 17, 2018:

• CMS to conduct new survey on post-op visits in global surgical codes

• Are you smarter than DataDerm™?

• ICD-10 updates impact several MIPS quality measures

• CMS to waive Medicare requirements for providers affected by Hurricane Michael

• Academy seeks statements on proposed bylaws amendments

• Help the Academy keep dermatology’s voice strong: Join the AMA

October 10, 2018:

• CMS to make physicians’ offices fax-free by 2020

• Are you smarter than DataDerm™?

• Issue breakdown: Compounding standard would disrupt care

• AI trained to classify common dermatopathology diagnoses

• AAD updates “Find a Dermatologist” tool — have you updated your profile?

• Study suggests minority residents face extra workplace burdens

October 3, 2018:

• Budget bill includes wins for dermatology

• AAD updates “Find a Dermatologist” tool — have you updated your profile?

• Are you smarter than DataDerm™?

• Did CMS miscalculate your MIPS?

• Perioral rejuvenation with hyaluronic acid fillers improved projected first impressions

September 26, 2018

• Drug prices spike after shortages

• September Access Hero: Dr. Jonathan Silverberg

• Dupilumab improves adolescent atopic dermatitis, quality of life

September 19, 2018

• More than 25% of Americans surveyed think psoriasis is contagious

• What did the AADA have to say about the proposed fee schedule?

• Atopic dermatitis associated with depression, anxiety, and suicidal ideation

• Have you joined the JAAD Journal Club yet?

• Risk for surgical-site infection increased in lower extremity Mohs surgery

September 12, 2018

• CMS continues to tinker with MIPS in 2019 proposal

• Experimental acne vaccine targets skin bacteria

• Call for nominations deadline is Oct. 1

• Hospitals launch generic drug company

• Rosacea is drastically underdiagnosed, according to study

• How effective are natural ingredients at UV protection?

• Voice your opposition about repealing the indoor tanning tax

September 5, 2018

• CMS values virtual visits

• AMA House of Delegates votes on critical health policy resolutions 

• High drug costs send patients seeking foreign medications

• FDA approves tretinoin lotion for acne

• Brief dermatologist intervention increases sunscreen use, patient satisfaction

August 29, 2018

• CMS questions global payment codes

• Non-physician clinicians bill more dermatologic procedures

• Can machine learning exacerbate health care disparities in dermatology?

• Mediterranean diet may help ease psoriasis severity

• Compounds in maple leaves may prevent wrinkles

August 22, 2018

• 6 new biopsy codes for 2019

• August Access Hero: Jessica Burgy, MD

• Submit your comments on psoriasis draft guidelines

• 2018 QPP exception applications now available

• Ortho Dermatologics resubmits New Drug Application for plaque psoriasis lotion

August 15, 2018

• The good, the bad, and the unknown in CMS E/M proposals 

• DataDerm™: Better your practice, better the specialty

• FDA approves new drug to treat cutaneous T-cell lymphoma

• Dermatologist compensation growth stalls in 2017, survey shows

• 2017 MIPS performance feedback and payment adjustment

• Brent Moody, MD, wins Republican primary in Tennessee 

August 8, 2018

• Fee schedule: The good, the bad, and the ugly 

• August Access Hero: Cory Simpson, MD

• USP publishes proposed revisions to chapter on compounded sterile preparations

• CDC offers infection prevention guide as patient infection incidents increase

• Severity of atopic dermatitis tied to risk of cataracts among pediatric patients

• Tickborne diseases are likely to increase, warn NIH officials

August 1, 2018

• Physicians suing patients over negative reviews

• FDA to laser device manufacturers: Stop marketing for vaginal rejuvenation

• FDA releases biosimilars plan to increase access, encourage competition

• Blood test may be able to detect melanoma

• Health care cyberattacks on the rise, sensitive data exposed

• FDA grants orphan drug status to dermatomyositis drug

July 25, 2018:

• FDA takes steps to address, prevent drug shortages 

• Distinction between inflammatory, neuropathic pruritus relevant for care

• Melanoma underreported among dermatopathologists

• Drugmakers rescind price hikes after California law takes effect

July 18, 2018:

• FDA approves first topical hyperhidrosis treatment

• CMS proposes major E/M changes, modifier 25 payment reduction: What’s next?

• Survey indicates residents lack confidence in coding, billing skills

• ‘Gag clauses’ cause some to pay more for drugs

• Skin Cancer Prevention Report shows progress, room for improvement

• Could the HPV vaccine treat squamous cell carcinoma?

• FDA warns against use of sterile drug products 

July 11, 2018:

• Amazon upends drug market with purchase of online pharmacy

• JAAD paper reviews research on chemical sunscreen and the environment

• Clarification: FDA response to topical psoriasis treatment application

• CMS posts 2017 Open Payments data

• Novel targets, treatments needed for metastatic melanoma

• FDA commissioner gives statement about compounded drugs

• Trump administration threatens drug manufacturers 

July 4, 2018:

• iPLEDGE hits a snag with patients

• Hawaii governor signs legislation banning sunscreen with oxybenzone and octinoxate

• Medicare announces new MUE limit for aminolevulinic acid HCI, 10%

• How did you fare with MIPS in 2017? Take a look

• FDA withdraws draft guidance on biosimilars

• Is there a connection between HS and Crohn’s?

June 27, 2018:

• FDA does not approve topical psoriasis treatment

• Medicare to limit reimbursement for aminolevulinic acid HCI, 10%

• Senators urge FDA to examine drug shortages

• Sen. Schumer works to pull ‘sunscreen pills’ from market

• NEW: Urticaria guidelines

• 2019 committee appointment application now open

June 20, 2018:

• Robots in medicine are coming, but at what cost?

• June Access Hero: Dr. Colven

• Does benzoyl peroxide stain all fabrics?

• CMS launches new Medicare Card search tool

• Despite the risks, patients are willing to share their data

• 2019 committee appointment application now open

June 13, 2018:

• FDA approves first hyaluronic acid filler for hands

• Feedback requested: Primary cutaneous melanoma treatment draft guidelines

• After 60 years, a new treatment for pemphigus vulgaris

• Jack Resneck Jr., MD, re-elected to AMA Board of Trustees

• Older patients slowly warming to telemedicine

• 2019 committee appointment application now open

June 6, 2018:

• Feedback requested: Primary cutaneous melanoma treatment draft guidelines

• Integrating the human touch at the AAD Annual Meeting

• Insurer reverses onerous isotretinoin policy

• FDA issues REMS draft guidance for manufacturers

• CMS releases QPP participation results

• EB treatment receives rare pediatric disease designation from FDA

• 2019 committee appointment application now open

May 30, 2018:

• FDA issues warning on unapproved sunscreen pills

• May Access Hero: Karen Edison, MD

• Study: AI detects skin cancer better than dermatologists

• BCBS Michigan rescinds modifier 25 reimbursement reduction policy

• Medical school enrollment is up, but can residency slots keep pace?

• FDA approves new biologic for psoriasis

• 2019 committee appointment application now open

May 23, 2018:

• FDA declines to approve potential frown line treatment

• AAD Annual Meetings: Vital to resident education and the future of dermatology

• Dermatologist wins Republican nomination in Pennsylvania congressional primary race

• VA gives physicians the green light to practice telemedicine across state lines

• FDA eyeballs artificial intelligence in medicine

• 2019 committee appointment application now open

May 16, 2018:

• Is your group eligible for MIPS? You’d better check.

• Be a Skin Cancer Hero this May

• AADA plans to comment on Trump drug-price proposals

• Can technology help with treatment adherence?

• 2019 committee appointment application now open

May 9, 2018:

• FDA grants lidocaine HCL 1% approval to Spectra Medical

• AAD Board selects Daniel D. Bennett, MD, as next assistant secretary-treasurer

• Hawaii passes legislation banning sunscreen with oxybenzone and octinoxate

• Study shows reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel

• Academy Advisory Board invites members to submit policy resolutions

• 2019 committee appointment application now open

May 2, 2018:

• The clock is ticking: Only a few days left to review your Sunshine Act info

• PBMs cutting copay coupons from patient deductibles — which could mean soaring prices for your biologics patients

• The latest cosmetic trend: Preventative Botox

• CMS to change name of MIPS EHR section

• Want to know how much your patients’ prescriptions will cost? There’s an app for that.

• 2019 committee appointment application now open

April 25, 2018:

• Who’s better at diagnosing skin cancer: PAs or dermatologists?

• How is MIPS affecting you? CMS wants to know.

• New physician compensation report: How does dermatology fare?

• Medicare erroneously paid for telehealth services

• 2019 committee appointment application now open

April 18, 2018:

• Getting too many calls from pharmacists? It could get worse.

• April Access Hero: Dr. Van Voorhees

• 2019 committee appointment application now open

• Not sure you’re eligible for MIPS? Better check.

• Help wanted: AAD Pruritus Measure Testing Project

April 11, 2018:

• How did you fare with MIPS? Take a look.

• Help wanted: AAD Pruritus Measure Testing Project

• Indoor tanning bed users not getting screened

• What is the economic impact of inappropriate cellulitis tests?

• CDC breaks down HIV incidence, prevalence among MSM

• HHS launches new initiative to boost patient medical record access

April 4, 2018:

• Deadline approaching: Review your Sunshine Act info

• New Medicare card transition to begin this month

• FDA seeks methods to improve biosimilar pathway

• iPLEDGE REMS program website experiencing issues

• Wife of Surgeon General undergoing surgery for recurrent metastatic melanoma

• New: Guidelines for evaluating hirsutism

• Does weight affect onychomycosis risk?

March 28, 2018:

• The burden of prior authorizations: Is it really that bad?

• Take the ABMS survey on MOC

• Help wanted: AAD Pruritus Measure Testing Project

• FDA approves new psoriasis biologic

• Health care cyberattacks on the rise

• When do copayments cost more than drugs? Fairly often, study shows.

March 21, 2018:

• Walgreens sued over generic drug prices

• March Access Hero: Dr. Chong

• Help wanted: AAD Pruritus Measure Testing Project

• Deadline for 2017 MIPS data submission

• New poll shows patient-physician communication disconnect

• USPSTF issues recommendations on skin cancer prevention counseling

• Help AADA, AMA rein in burdensome regulations, harmful payer policies

March 14, 2018:

• FDA approves anti-fungal agent for pediatric patients

• Bruce H. Thiers, MD, elected incoming president-elect

• Open Payments review starts next month: Are you ready?

• Melanoma incidence among young, white women declines drastically

• New Medicare cards: Educate your patients while they wait

• FDA to inspect Cantrell Drug Co. compounding facility

• Pulse check: How are EHR systems faring on interoperability?

March 7, 2018:

• Is MIPS a burden? Tell CMS and get full credit in 2018.

• Academy election results announced

• ABD requests Mohs subspecialty certification

• AAD relocates headquarters

• Conversion therapy still common for LGBT population

Feb. 28, 2018:

• Another win for dermatology: Anthem rescinds proposed modifier 25 policy

• Vote in the AAD election by March 3

• FDA grants rituximab priority review for pemphigus vulgaris

• CMS eases up on value-based payment focus

• Do EHRs reduce administrative costs?

• Laser treatment may improve nail psoriasis severity

Feb. 21, 2018:

• CMS releases MIPS quality performance scores

• AAD election

• Study indicates e-consults improve access to dermatology

• How helpful is federal research funding?

• Water systems tainted for many Americans

Feb. 14, 2018:

• A win for dermatology: Congress repeals IPAB, stops misvalued codes policy

• Vote in the AAD election by March 3

• Are machines poised to replace physicians?

• Countdown to official Medicare card transition

• Do pediatric psoriasis patients have a greater risk of developing obesity?

Feb. 7, 2018:

• Generic drug prices: What to expect in 2018

• February Access Hero: Dr. Brodell

• CMS expands ‘Extreme and Uncontrollable Circumstances’ policy

• Network inaccuracies worsen

• Fewer physicians opting out of Medicare

Jan. 31, 2018:

• First IGA scale for EB simplex validated

• AAD election candidates announced

• FDA to revise draft guidance affecting in-office preparations

• How do different SPFs compare?

• Alex Azar confirmed as HHS Secretary

• NMQF accepting nominations for Leaders in Minority Health Awards

Jan. 24, 2018:

• Psoriasis treatments: Which ones are the most effective?

• AAD names Dirk Elston, MD, next JAAD editor

• SCC death reports may be inaccurate

• Does adherence vary by treatment?

• Where are the tanning salons?

Jan. 17, 2018:

• How does the new tax reform law affect your practice?

• HHS 2018 regulatory agenda includes sunscreen, sunlamps

• Patients sue health insurer

• New Advanced APM approved

Jan. 10, 2018:

• Academy releases new NMSC clinical guidelines

• Stem cell transplants for scleroderma patients may improve survival, quality of life

• CMS launches new QPP data submission program

• Drug approvals: FDA steps on the gas

• AD drug receives FDA breakthrough therapy status

Jan. 3, 2018:

• Anthem delays, changes modifier 25 cuts

• FDA approves PD-1 inhibitor for melanoma

• Spending on drugs slowed in 2016

• Countdown to Medicare card transition begins

• Health care discrepancies may exist for Native Americans